Literature DB >> 25315249

Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity.

Phyllis F Y Cheung1, Chi Wai Yip1, Nicholas C L Wong2, Daniel Y T Fong3, Linda W C Ng2, Angus M Y Wan2, Chun Kwok Wong4, Tan To Cheung5, Irene O L Ng6, Ronnie T P Poon7, Sheung Tat Fan7, Siu Tim Cheung8.   

Abstract

Immunoevasion is an emerging hallmark of cancer. Impairment of natural killer (NK) cytotoxicity is a mechanism to evade host immunosurveillance. Granulin-epithelin precursor (GEP) is a hepatic oncofetal protein regulating growth, invasion, and chemoresistance in hepatocellular carcinoma (HCC). We examined the role of GEP in conferring HCC cells the ability to evade NK cytotoxicity. In HCC cell lines, GEP overexpression reduced, whereas GEP suppression enhanced sensitivity to NK cytotoxicity. GEP downregulated surface expression of MHC class I chain-related molecule A (MICA), ligand for NK stimulatory receptor NK group 2 member D (NKG2D), and upregulated human leukocyte antigen-E (HLA-E), ligand for NK inhibitory receptor CD94/NKG2A. Functionally, GEP augmented production of soluble MICA, which suppressed NK activation. Matrix metalloproteinase (MMP)2 and MMP9 activity was involved partly in the GEP-regulated MICA shedding from HCC cells. In primary HCCs (n = 80), elevated GEP (P < 0.001), MICA (P < 0.001), and HLA-E (P = 0.089) expression was observed when compared with those in nontumor (n = 80) and normal livers (n = 10). Serum GEP (P = 0.010) and MICA (P < 0.001) levels were higher in patients with HCC (n = 80) than in healthy individuals (n = 30). High serum GEP and/or MICA levels were associated with poor recurrence-free survival (log-rank test, P = 0.042). Importantly, GEP blockade by mAbs sensitized HCC cells to NK cytotoxicity through MICA. In summary, GEP rendered HCC cells resistant to NK cytotoxicity by modulating MICA expression, which could be reversed by GEP blockade using antibody. Serum GEP and MICA levels are prognostic factors and can be used to stratify patients for targeted therapy. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25315249     DOI: 10.1158/2326-6066.CIR-14-0096

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  15 in total

1.  High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer.

Authors:  Cheng Sun; Jing Xu; Qiang Huang; Mei Huang; Hao Wen; Chuanshan Zhang; Jinyu Wang; Jiaxi Song; Meijuan Zheng; Haoyu Sun; Haiming Wei; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

Review 2.  Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases.

Authors:  Yazhou Cui; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2019-01-30       Impact factor: 7.638

Review 3.  Progranulin and its biological effects in cancer.

Authors:  Fabian Arechavaleta-Velasco; Carlos Eduardo Perez-Juarez; George L Gerton; Laura Diaz-Cueto
Journal:  Med Oncol       Date:  2017-11-07       Impact factor: 3.064

4.  Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments.

Authors:  Elisabetta Cariani; Massimo Pilli; Valeria Barili; Emanuela Porro; Elisabetta Biasini; Andrea Olivani; Raffaele Dalla Valle; Tommaso Trenti; Carlo Ferrari; Gabriele Missale
Journal:  Oncoimmunology       Date:  2016-03-04       Impact factor: 8.110

5.  Progranulin promotes melanoma progression by inhibiting natural killer cell recruitment to the tumor microenvironment.

Authors:  Ramouna Voshtani; Mei Song; Huan Wang; Xiaoqi Li; Wei Zhang; Mojdeh S Tavallaie; Wenjun Yan; Joseph Sun; Fang Wei; Xiaojing Ma
Journal:  Cancer Lett       Date:  2019-09-03       Impact factor: 8.679

Review 6.  An update of biochemical markers of hepatocellular carcinoma.

Authors:  Abdulaziz Ajlan M AlSalloom
Journal:  Int J Health Sci (Qassim)       Date:  2016-01

Review 7.  Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.

Authors:  Terence Kin-Wah Lee; Xin-Yuan Guan; Stephanie Ma
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-09       Impact factor: 46.802

8.  Restoration of natural killer activity in hepatocellular carcinoma by treatment with antibody against granulin-epithelin precursor.

Authors:  Phyllis Fy Cheung; Chi Wai Yip; Linda Wc Ng; Chun Kwok Wong; Tan To Cheung; Chung Mau Lo; Sheung Tat Fan; Siu Tim Cheung
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

9.  Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line.

Authors:  Phyllis F Y Cheung; Chi Wai Yip; Linda W C Ng; Kwok Wai Lo; Chit Chow; Kui Fat Chan; Tan To Cheung; Siu Tim Cheung
Journal:  Cancer Cell Int       Date:  2016-06-08       Impact factor: 5.722

10.  Carcinogenic Parasite Secretes Growth Factor That Accelerates Wound Healing and Potentially Promotes Neoplasia.

Authors:  Michael J Smout; Javier Sotillo; Thewarach Laha; Atiroch Papatpremsiri; Gabriel Rinaldi; Rafael N Pimenta; Lai Yue Chan; Michael S Johnson; Lynne Turnbull; Cynthia B Whitchurch; Paul R Giacomin; Corey S Moran; Jonathan Golledge; Norelle Daly; Banchob Sripa; Jason P Mulvenna; Paul J Brindley; Alex Loukas
Journal:  PLoS Pathog       Date:  2015-10-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.